Curcumin-based Therapies for Chronic Conditions

The inventive concept leverages the core technology of curcumin as an NK3 antagonist to address unmet needs in various chronic conditions, including fibromyalgia, rheumatoid arthritis, irritable bowel syndrome, menopause, and post-traumatic stress disorder.

The original patent disclosed curcumin compositions and methods of use as an NK3 antagonist, primarily focusing on the central nervous system. However, the patent's limitations in addressing chronic conditions outside the CNS domain led to the development of this new inventive concept, which applies the core technology to entirely different industries and fields.

The inventive concept comprises a curcumin composition as an NK3 antagonist, which is combined with various adjunct therapies, devices, or regimens to target specific chronic conditions. For instance, the system for treating chronic pain in patients with fibromyalgia combines the curcumin composition with a wearable device for monitoring pain levels. Similarly, the method for reducing inflammation in patients with rheumatoid arthritis involves administering the curcumin composition alongside a physical therapy regimen.

The new claims introduce a novel application of curcumin as an NK3 antagonist in treating chronic conditions outside the CNS domain, which is non-obvious compared to the original patent's focus on the CNS. The inventive concept's combination of the curcumin composition with various adjunct therapies, devices, or regimens provides a unique solution for addressing these chronic conditions.

Alternative embodiments of the inventive concept could include different formulations of the curcumin composition, varying ratios of the curcumin composition to the adjunct therapies, devices, or regimens, or the use of different NK3 antagonists. Variations could also involve targeting other chronic conditions, such as chronic obstructive pulmonary disease or inflammatory bowel disease.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, with a target market encompassing patients suffering from chronic conditions. The estimated market size for fibromyalgia alone is projected to reach $1.4 billion by 2025, and the inventive concept's ability to address unmet needs in this space positions it for substantial market share.